2-(5-chloro-2-methyl-1H-indol-3-yl)-N,N-dimethylethanamine: a 5-HT6 receptor agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9921064 |
| CHEMBL ID | 365751 |
| SCHEMBL ID | 1817642 |
| MeSH ID | M0557579 |
| Synonym |
|---|
| CHEMBL365751 , |
| bdbm50171234 |
| [2-(5-chloro-2-methyl-1h-indol-3-yl)-ethyl]-dimethyl-amine |
| SCHEMBL1817642 |
| st1936 |
| st1936, >=98% (hplc) |
| NCGC00379109-01 |
| 1210-81-7 |
| Q15410182 |
| st-1936 , |
| 2-(5-chloro-2-methyl-1h-indol-3-yl)-n,n-dimethylethanamine |
| 5-chloro-n,n,2-trimethyl-1h-indole-3-ethanamine |
| 4r5znv2chc , |
| 1h-indole-3-ethanamine, 5-chloro-n,n,2-trimethyl- |
| unii-4r5znv2chc |
| MS-23379 |
| HY-103110 |
| BAA21081 |
| CS-0024372 |
| DTXSID001045649 |
| AKOS040745374 |
| uql , |
| 2-(5-chloranyl-2-methyl-1~{h}-indol-3-yl)-n,n-dimethyl-ethanamine |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 3.3786 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.3000 | 0.0001 | 0.8074 | 10.0000 | AID1249628 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3000 | 0.0001 | 0.9490 | 10.0000 | AID1249627 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.3000 | 0.0002 | 0.7257 | 10.0000 | AID1249628 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.3000 | 0.0003 | 0.4834 | 10.0000 | AID1249628 |
| Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3000 | 0.0000 | 0.9296 | 10.0000 | AID1249629 |
| Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3000 | 0.0000 | 0.9708 | 10.0000 | AID1249629 |
| Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3000 | 0.0000 | 0.9375 | 10.0000 | AID1249629 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3000 | 0.0000 | 0.5751 | 10.0000 | AID1249627 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | Ki | 0.0288 | 0.0002 | 0.4254 | 2.1000 | AID1249622 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.2900 | 0.0003 | 0.3806 | 10.0000 | AID1249626 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.2450 | 0.0003 | 0.7693 | 10.0000 | AID1249624 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.3000 | 0.0000 | 0.9650 | 10.0000 | AID1249627 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 (µMol) | 0.0400 | 0.0017 | 0.8381 | 5.4200 | AID254956 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | EC50 (µMol) | 0.0448 | 0.0001 | 0.0096 | 0.0448 | AID1249617 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1249622 | Displacement of [3H] lysergic acid diethylamide from rat 5-HT6 receptor transfected in HEK293 cells after 60 mins by scintillation counter | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID1249629 | Binding affinity to rat alpha2 adrenergic receptor | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID1249628 | Binding affinity to human recombinant alpha2 adrenergic receptor | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID1249627 | Binding affinity to rat alpha1 adrenergic receptor | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID255635 | Concentration to stimulate the cAMP production in BHK cells | 2005 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19 | 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. |
| AID1249617 | Agonist activity at 5-HT6 receptor (unknown origin) | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID1249625 | Selectivity ratio of Ki for 5-HT7 receptor (unknown origin) to Ki for rat 5-HT6 receptor | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID1249626 | Binding affinity to 5-HT7 receptor (unknown origin) | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID1249623 | Selectivity ratio of Ki for 5-HT2B receptor (unknown origin) to Ki for rat 5-HT6 receptor | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID255427 | Intrinsic activity (IA) at the 5-HT6 receptor determined by measuring their cAMP production in BHK cells and compared to the effect elicited by 5-HT | 2005 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19 | 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. |
| AID1249624 | Binding affinity to 5-HT2B receptor (unknown origin) | 2015 | Journal of medicinal chemistry, Oct-22, Volume: 58, Issue:20 | Therapeutic Potential of 5-HT6 Receptor Agonists. |
| AID254956 | Displacement of [3H]LSD binding to cloned human 5-hydroxytryptamine 6 receptor expressed in HEK cells | 2005 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19 | 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.08) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||